Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence

References

• Siegel R Naishadham D Jemal A Cancer statistics, 2013 CA Cancer J Clin 2013 63 1 11 30 23335087
   PubMed Web of Science ®Google Scholar
• Siegel R DeSantis C Virgo K Cancer treatment and survivorship statistics, 2012 CA Cancer J Clin 2012 62 4 220 241 22700443
   PubMed Web of Science ®Google Scholar
• Schiller JH Harrington D Belani CP Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 2002 346 2 92 98 11784875
   PubMed Web of Science ®Google Scholar
• Ohe Y Ohashi Y Kubota K Randomized Phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan Ann Oncol 2007 18 2 317 323 17079694
   PubMed Web of Science ®Google Scholar
• Pao W Chmielecki J Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer Nat Rev Cancer 2010 10 11 760 774 20966921
   PubMed Web of Science ®Google Scholar
• Fukuoka M Yano S Giaccone G Multi-institutional randomized Phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected] J Clin Oncol 2003 21 12 2237 2246 12748244
   PubMed Web of Science ®Google Scholar
• Kris MG Natale RB Herbst RS Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial JAMA 2003 290 16 2149 2158 14570950
   PubMed Web of Science ®Google Scholar
• Thatcher N Chang A Parikh P Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 2005 366 9496 1527 1537 16257339
   PubMed Web of Science ®Google Scholar
• Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 2004 350 21 2129 2139 15118073
   PubMed Web of Science ®Google Scholar
• Paez JG Janne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 15118125
   PubMed Web of Science ®Google Scholar
• Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 2004 101 36 13306 13311 15329413
   PubMed Web of Science ®Google Scholar
• Fukuoka M Wu YL Thongprasert S Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 2011 29 21 2866 2874 21670455
   PubMed Web of Science ®Google Scholar
• Mok TS Wu YL Thongprasert S Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma N Engl J Med 2009 361 10 947 957 19692680
   PubMed Web of Science ®Google Scholar
• Shepherd FA Rodrigues Pereira J Ciuleanu T Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 2005 353 2 123 132 16014882
   PubMed Web of Science ®Google Scholar
• Barker AJ Gibson KH Grundy W Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 2001 11 14 1911 1914 11459659
   PubMed Web of Science ®Google Scholar
• Moyer JD Barbacci EG Iwata KK Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase Cancer Res 1997 57 21 4838 4848 9354447
   PubMed Web of Science ®Google Scholar
• Rosell R Moran T Queralt C Screening for epidermal growth factor receptor mutations in lung cancer N Engl J Med 2009 361 10 958 967 19692684
   PubMed Web of Science ®Google Scholar
• Cortes-Funes H Gomez C Rosell R Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients Ann Oncol 2005 16 7 1081 1086 15851406
   PubMed Web of Science ®Google Scholar
• Mitsudomi T Kosaka T Endoh H Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 2005 23 11 2513 2520 15738541
   PubMed Web of Science ®Google Scholar
• Han SW Kim TY Jeon YK Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation Clin Cancer Res 2006 12 8 2538 2544 16638863
   PubMed Web of Science ®Google Scholar
• Mitsudomi T Yatabe Y Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer Cancer Sci 2007 98 12 1817 1824 17888036
   PubMed Web of Science ®Google Scholar
• Roengvoraphoj M Tsongalis GJ Dragnev KH Rigas JR Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients Cancer Treat Rev 2013 39 8 839 850 23768755
   PubMed Web of Science ®Google Scholar
• Jackman DM Yeap BY Sequist LV Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib Clin Cancer Res 2006 12 13 3908 3914 16818686
   PubMed Web of Science ®Google Scholar
• Riely GJ Pao W Pham D Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib Clin Cancer Res 2006 12 3 Pt 1 839 844 16467097
   PubMed Web of Science ®Google Scholar
• Lee VH Tin VP Choy TS Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer J Thorac Oncol 2013 8 9 1148 1155 23945384
   PubMed Web of Science ®Google Scholar
• Yasuda H Park E Yun CH Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer Sci Transl Med 2013 5 216 216ra177
   PubMed Web of Science ®Google Scholar
• Hall JG Eis PS Law SM Sensitive detection of DNA polymorphisms by the serial invasive signal amplification reaction Proc Natl Acad Sci U S A 2000 97 15 8272 8277 10890904
   PubMed Web of Science ®Google Scholar
• Nagai Y Miyazawa H Huqun Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp Cancer Res 2005 65 16 7276 7282 16105816
   PubMed Web of Science ®Google Scholar
• Yatabe Y Hida T Horio Y Kosaka T Takahashi T Mitsudomi T A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer J Mol Diagn 2006 8 3 335 341 16825506
   PubMed Web of Science ®Google Scholar
• Kimura H Kasahara K Kawaishi M Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer Clin Cancer Res 2006 12 13 3915 3921 16818687
   PubMed Web of Science ®Google Scholar
• Goto K Satouchi M Ishii G An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting Ann Oncol 2012 23 11 2914 2919 22776705
   PubMed Web of Science ®Google Scholar
• Zhou C Wu YL Chen G Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, Phase III study Lancet Oncol 2011 12 8 735 742 21783417
   PubMed Web of Science ®Google Scholar
• Rosell R Carcereny E Gervais R Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised Phase III trial Lancet Oncol 2012 13 3 239 246 22285168
   PubMed Web of Science ®Google Scholar
• Wu YL Liam CK Zhou C First-line erlotinib versus cisplatin/gemcitabine (GP) in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC): interim analyses from the Phase III, open-label, ENSURE study J Thorac Oncol 2013 8 Suppl 2 S603
   Google Scholar
• Chen G Feng J Zhou C Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a Phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) Ann Oncol 2013 24 6 1615 1622 23456778
   PubMed Web of Science ®Google Scholar
• Yamada K Takayama K Kawakami S Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803) Jpn J Clin Oncol 2013 43 6 629 635 23599349
   PubMed Web of Science ®Google Scholar
• Goto K Nishio M Yamamoto N A prospective, Phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC) Lung Cancer 2013 82 1 109 114 23910906
   PubMed Web of Science ®Google Scholar
• Katakami N Morita S Yoshioka H Randomized Phase III study comparing gefitinib (G) with erlotinib (E) in patients (pts) with previously treated advanced lung adenocarcinoma (LA): WJOG 5108L [abstract] J Clin Oncol 2014 32 Suppl 5 8041
   Web of Science ®Google Scholar
• Zhu CQ da Cunha Santos G Ding K Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 2008 26 26 4268 4275 18626007
   PubMed Web of Science ®Google Scholar
• Yoshioka H Hotta K Kiura K A Phase II trial of erlotinib monotherapy in pretreated patients with advanced non-small cell lung cancer who do not possess active EGFR mutations: Okayama Lung Cancer Study Group trial 0705 J Thorac Oncol 2010 5 1 99 104 19898258
   PubMed Web of Science ®Google Scholar
• Matsuura S Inui N Ozawa Y Phase II study of erlotinib as third-line monotherapy in patients with advanced non-small-cell lung cancer without epidermal growth factor receptor mutations Jpn J Clin Oncol 2011 41 8 959 963 21715361
   PubMed Web of Science ®Google Scholar
• Karampeazis A Voutsina A Souglakos J Pemetrexed versus erlotinib in pretreated patients with advanced non-small cell lung cancer: a Hellenic Oncology Research Group (HORG) randomized Phase III study Cancer 2013 119 15 2754 2764 23661337
   PubMed Web of Science ®Google Scholar
• Jazieh AR Al Sudairy R Abu-Shraie N Al Suwairi W Ferwana M Murad MH Erlotinib in wild type epidermal growth factor receptor non-small cell lung cancer: a systematic review Ann Thorac Med 2013 8 4 204 208 24250733
   PubMed Web of Science ®Google Scholar
• Garassino MC Martelli O Broggini M Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial Lancet Oncol 2013 14 10 981 988 23883922
   PubMed Web of Science ®Google Scholar
• Kawaguchi T Ando M Asami K Randomized Phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) J Clin Oncol 2014 32 18 1902 1908 24841974
   PubMed Web of Science ®Google Scholar
• Ishii Y Maemondo M Okudera K A Phase II study of erlotinib monotherpay in patients with previously treated advanced non-small cell lung cancer (NSCLC) without EGFR gene mutation who have never/light smoking history: NEJ006/TCOG0903 [abstract] J Clin Oncol 2012 30 Suppl 7561
   Google Scholar
• Yonesaka K Zejnullahu K Lindeman N Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers Clin Cancer Res 2008 14 21 6963 6973 18980991
   PubMed Web of Science ®Google Scholar
• Chang MH Ahn HK Lee J Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors Cancer 2011 117 1 143 151 20803614
   PubMed Web of Science ®Google Scholar
• Addison CL Ding K Zhao H Plasma transforming growth factor alpha and amphiregulin protein levels in NCIC Clinical Trials Group BR.21 J Clin Oncol 2010 28 36 5247 5256 21079146
   PubMed Web of Science ®Google Scholar
• Inoue A Kobayashi K Usui K First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 2009 27 9 1394 1400 19224850
   PubMed Web of Science ®Google Scholar
• Lee SM Khan I Upadhyay S First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, Phase III trial Lancet Oncol 2012 13 11 1161 1170 23078958
   PubMed Web of Science ®Google Scholar
• Gridelli C Maione P Rossi A Potential treatment options after first-line chemotherapy for advanced NSCLC: maintenance treatment or early second-line? Oncologist 2009 14 2 137 147 19190239
   PubMed Web of Science ®Google Scholar
• Sandler A Gray R Perry MC Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 2006 355 24 2542 2550 17167137
   PubMed Web of Science ®Google Scholar
• Ciuleanu T Brodowicz T Zielinski C Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, Phase III study Lancet 2009 374 9699 1432 1440 19767093
   PubMed Web of Science ®Google Scholar
• Paz-Ares L de Marinis F Dediu M Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, Phase III, randomised controlled trial Lancet Oncol 2012 13 3 247 255 22341744
   PubMed Web of Science ®Google Scholar
• Paz-Ares LG de Marinis F Dediu M PARAMOUNT: final overall survival results of the Phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer J Clin Oncol 2013 31 23 2895 2902 23835707
   PubMed Web of Science ®Google Scholar
• Cappuzzo F Ciuleanu T Stelmakh L Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase III study Lancet Oncol 2010 11 6 521 529 20493771
   PubMed Web of Science ®Google Scholar
• Jackman D Pao W Riely GJ Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 2010 28 2 357 360 19949011
   PubMed Web of Science ®Google Scholar
• Herbst RS Prager D Hermann R TRIBUTE: a Phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 2005 23 25 5892 5899 16043829
   PubMed Web of Science ®Google Scholar
• Gatzemeier U Pluzanska A Szczesna A Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 2007 25 12 1545 1552 17442998
   PubMed Web of Science ®Google Scholar
• Mok TS Wu YL Yu CJ Randomized, placebo-controlled, Phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer J Clin Oncol 2009 27 30 5080 5087 19738125
   PubMed Web of Science ®Google Scholar
• Li T Ling YH Goldman ID Perez-Soler R Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 2007 13 11 3413 3422 17545550
   PubMed Web of Science ®Google Scholar
• Wu YL Lee JS Thongprasert S Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial Lancet Oncol 2013 14 8 777 786 23782814
   PubMed Web of Science ®Google Scholar
• Kanda S Ohe Y Horinouchi H Phase II study of gefitinib and inserted cisplatin plus docetaxel as a first-line treatment for advanced non-small cell lung cancer haboring an epidermal growth factor receptor activating mutation [abstract] J Clin Oncol 2013 31 Suppl 8064
   Google Scholar
• Herbst RS Ansari R Bustin F Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, Phase III trial Lancet 2011 377 9780 1846 1854 21621716
   PubMed Web of Science ®Google Scholar
• Kato T Seto T Nishio M Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive nonsquamous non-small cell lung cancer (NSCLC): an open-label randomized trial [abstract] J Clin Oncol 2014 32 Suppl 5 8005
   Web of Science ®Google Scholar
• Chaft JE Oxnard GR Sima CS Kris MG Miller VA Riely GJ Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design Clin Cancer Res 2011 17 19 6298 6303 21856766
   PubMed Web of Science ®Google Scholar
• Kuo CH Lin SM Lee KY Subsequent chemotherapy improves survival outcome in advanced non-small-cell lung cancer with acquired tyrosine kinase inhibitor resistance Clin Lung Cancer 2010 11 1 51 56 20085868
   PubMed Web of Science ®Google Scholar
• Solca F Dahl G Zoephel A Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J Pharmacol Exp Ther 2012 343 2 342 350 22888144
   PubMed Web of Science ®Google Scholar
• Schiller JH Akerley WL Brugger W Results from ARQ 197–209: a global randomized placebo-controlled Phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) [abstract] J Clin Oncol 2010 28 Suppl 18 LBA7502
   Web of Science ®Google Scholar
• Spigel DR Ervin TJ Ramlau R Final efficacy results from OAM4558g, a randomized Phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC [abstract] J Clin Oncol 2011 29 Suppl 7505
   Web of Science ®Google Scholar
• Nishie K Kawaguchi T Tamiya A Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations J Thorac Oncol 2012 7 11 1722 1727 23059777
   PubMed Web of Science ®Google Scholar
• Yu HA Sima CS Huang J Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors J Thorac Oncol 2013 8 3 346 351 23407558
   PubMed Web of Science ®Google Scholar
• Janne PA Wang X Socinski MA Randomized Phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial J Clin Oncol 2012 30 17 2063 2069 22547605
   PubMed Web of Science ®Google Scholar
• Arcila ME Oxnard GR Nafa K Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay Clin Cancer Res 2011 17 5 1169 1180 21248300
   PubMed Web of Science ®Google Scholar
• Yu HA Arcila ME Rekhtman N Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 2013 19 8 2240 2247 23470965
   PubMed Web of Science ®Google Scholar
• Hata A Katakami N Yoshioka H Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: comparison between T790M mutation-positive and mutation-negative populations Cancer 2013 119 24 4325 4332 24105277
   PubMed Web of Science ®Google Scholar
• Fabian MA Biggs WH3rd Treiber DK A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 2005 23 3 329 336 15711537
   PubMed Web of Science ®Google Scholar
• Kancha RK von Bubnoff N Peschel C Duyster J Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy Clin Cancer Res 2009 15 2 460 467 19147750
   PubMed Web of Science ®Google Scholar
• Cohen MH Williams GA Sridhara R Chen G Pazdur R FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets Oncologist 2003 8 4 303 306 12897327
   PubMed Web of Science ®Google Scholar
• Cohen MH Johnson JR Chen YF Sridhara R Pazdur R FDA drug approval summary: erlotinib (Tarceva) tablets Oncologist 2005 10 7 461 466 16079312
   PubMed Web of Science ®Google Scholar
• Nakagawa K Tamura T Negoro S Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (“Iressa”, ZD1839) in Japanese patients with solid malignant tumors Ann Oncol 2003 14 6 922 930 12796031
   PubMed Web of Science ®Google Scholar
• Yamamoto N Horiike A Fujisaka Y Phase I dose-finding and pharmacokinetic study of the oral epidermal growth factor receptor tyrosine kinase inhibitor Ro50-8231 (erlotinib) in Japanese patients with solid tumors Cancer Chemother Pharmacol 2008 61 3 489 496 17483950
   PubMed Web of Science ®Google Scholar
• Khuntia D Brown P Li J Mehta MP Whole-brain radiotherapy in the management of brain metastasis J Clin Oncol 2006 24 8 1295 1304 16525185
   PubMed Web of Science ®Google Scholar
• Langer CJ Mehta MP Current management of brain metastases, with a focus on systemic options J Clin Oncol 2005 23 25 6207 6219 16135488
   PubMed Web of Science ®Google Scholar
• Park SJ Kim HT Lee DH Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation Lung Cancer 2012 77 3 556 560 22677429
   PubMed Web of Science ®Google Scholar
• Togashi Y Masago K Fukudo M Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer J Thorac Oncol 2010 5 7 950 955 20479691
   PubMed Web of Science ®Google Scholar
• Togashi Y Masago K Masuda S Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer Cancer Chemother Pharmacol 2012 70 3 399 405 22806307
   PubMed Web of Science ®Google Scholar
• Lee E Keam B Kim DW Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer J Thorac Oncol 2013 8 8 1069 1074 23804027
   PubMed Web of Science ®Google Scholar
• Omuro AM Kris MG Miller VA High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib Cancer 2005 103 11 2344 2348 15844174
   PubMed Web of Science ®Google Scholar
• Paz-Ares L Soulieres D Melezinek I Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis J Cell Mol Med 2010 14 1–2 51 69 20015198
   PubMed Web of Science ®Google Scholar
• Takeda M Okamoto I Fukuoka M Nakagawa K Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity J Clin Oncol 2010 28 17 e273 e274 20385983
   PubMed Web of Science ®Google Scholar
• Kijima T Shimizu T Nonen S Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism J Clin Oncol 2011 29 19 e588 e590 21502555
   PubMed Web of Science ®Google Scholar
• Mitsudomi T Morita S Yatabe Y Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial Lancet Oncol 2010 11 2 121 128 20022809
   PubMed Web of Science ®Google Scholar
• Maemondo M Inoue A Kobayashi K Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 2010 362 25 2380 2388 20573926
   PubMed Web of Science ®Google Scholar
• Togashi Y Masago K Fujita S Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer Lung Cancer 2011 74 1 98 102 21377230
   PubMed Web of Science ®Google Scholar
• Soda M Choi YL Enomoto M Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer Nature 2007 448 7153 561 566 17625570
   PubMed Web of Science ®Google Scholar
• Shaw AT Kim DW Nakagawa K Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 2013 368 25 2385 2394 23724913
   PubMed Web of Science ®Google Scholar
• Yang JC Sequist LV Schuler MH Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): pooled analysis of two large open-label Phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) [abstract] J Clin Oncol 2014 32 Suppl 5 8004
   Web of Science ®Google Scholar
• Kobayashi S Boggon TJ Dayaram T EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 2005 352 8 786 792 15728811
   PubMed Web of Science ®Google Scholar
• Suda K Mizuuchi H Maehara Y Mitsudomi T Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation – diversity, ductility, and destiny Cancer Metastasis Rev 2012 31 3–4 807 814 22736441
   PubMed Web of Science ®Google Scholar
• Remon J Moran T Majem M Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: a new era begins Cancer Treat Rev 2014 40 1 93 101 23829935
   PubMed Web of Science ®Google Scholar